



Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August

LONDON, United Kingdom and SEATTLE, Wash., August [4], 2025 – [Tenpoint Therapeutics, Ltd.](#), a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company will participate in three upcoming investor conferences in August.

- **Oppenheimer & Co.'s 2025 Biotech in the Berkshires** is being held on August 4–6 in the Berkshires, MA. Tenpoint Therapeutics' President and Chief Business Officer Ben Bergo and Melissa Epperly, Chief Financial Officer, will present at 11:15am ET and host 1x1 meetings during the Conference.
- **Canaccord Genuity 45th Annual Growth Conference** is being held August 12–13 in Boston, MA. Henric Bjarke, Tenpoint Therapeutics' Chief Executive Officer, will present at 11:30am ET on August 13, and host 1x1 meetings during the Conference. The live event or replay can be accessed [here](#) or through the [Tenpoint Therapeutics](#) website.
- **H.C. Wainwright 5th Annual Ophthalmology Conference** is being held virtually on August 13. Ben Bergo, Tenpoint Therapeutics' President and CBO, will present and host virtual meetings throughout the day. A replay of the presentation can be accessed through the [Tenpoint Therapeutics](#) website.

To request a meeting with the Tenpoint Therapeutics team, please contact the respective conference representatives or email the Company's investor relations team at tenpoint@lavoiehealthscience.com.

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the NDA and has received a PDUFA date from US FDA of Jan 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life

Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG.

To learn more, visit tenpointtherapeutics.com and connect on [LinkedIn](#).

###

Contacts

Andrew Korda
LaVoieHealthScience
akorda@lavoiehealthscience.com
617-865-0043

Casey Darby
LaVoieHealthScience
tenpoint@lavoiehealthscience.com
847-964-3281